Takeda Drug For Lung Cancer Fails To Meet Phase III Goals
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical's motesanib, developed with U.S. drug maker Amgen, failed to pass Phase III goals for treating lung cancer